SpringWorks Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de SpringWorks Therapeutics es Saqib Islam , nombrado en Jul 2018, tiene una permanencia de 6.33 años. compensación anual total es $18.35M, compuesta por 4% salario y 96% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.93% de las acciones de la empresa, por valor de $27.05M. La antigüedad media del equipo directivo y de la junta directiva es de 4.5 años y 5.3 años, respectivamente.
Información clave
Saqib Islam
Chief Executive Officer (CEO)
US$18.4m
Compensación total
| Porcentaje del salario del CEO | 4.0% |
| Permanencia del CEO | 6.3yrs |
| Participación del CEO | 0.9% |
| Permanencia media de la dirección | 4.5yrs |
| Promedio de permanencia en la Junta Directiva | 5.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results
Nov 15
SpringWorks Therapeutics Merits A Speculative Buy
Nov 04SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy
Aug 07Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues
May 11We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
May 03SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
Apr 25SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners
Apr 19We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Sep 20We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate
Jun 07We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Feb 22Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Nov 09SpringWorks drops 21% as Allogene drops lead asset in combination study
Aug 10SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15
Aug 04Sizing Up SpringWorks Therapeutics
Jul 20Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?
Jun 06SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases
May 02Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth
Dec 30SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline
Dec 14SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business
Sep 15Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$275m |
| Jun 30 2024 | n/a | n/a | -US$301m |
| Mar 31 2024 | n/a | n/a | -US$339m |
| Dec 31 2023 | US$18m | US$725k | -US$325m |
| Sep 30 2023 | n/a | n/a | -US$305m |
| Jun 30 2023 | n/a | n/a | -US$298m |
| Mar 31 2023 | n/a | n/a | -US$289m |
| Dec 31 2022 | US$15m | US$680k | -US$277m |
| Sep 30 2022 | n/a | n/a | -US$259m |
| Jun 30 2022 | n/a | n/a | -US$228m |
| Mar 31 2022 | n/a | n/a | -US$206m |
| Dec 31 2021 | US$18m | US$590k | -US$174m |
| Sep 30 2021 | n/a | n/a | -US$107m |
| Jun 30 2021 | n/a | n/a | -US$87m |
| Mar 31 2021 | n/a | n/a | -US$60m |
| Dec 31 2020 | US$8m | US$541k | -US$46m |
| Sep 30 2020 | n/a | n/a | -US$73m |
| Jun 30 2020 | n/a | n/a | -US$68m |
| Mar 31 2020 | n/a | n/a | -US$62m |
| Dec 31 2019 | US$3m | US$480k | -US$51m |
| Sep 30 2019 | n/a | n/a | -US$41m |
| Jun 30 2019 | n/a | n/a | -US$29m |
| Mar 31 2019 | n/a | n/a | -US$18m |
| Dec 31 2018 | US$2m | US$407k | -US$18m |
Compensación vs. Mercado: La compensación total de Saqib($USD18.35M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD6.56M).
Compensación vs. Ingresos: La compensación de Saqib ha aumentado mientras la empresa no es rentable.
CEO
Saqib Islam (54 yo)
6.3yrs
Permanencia
US$18,351,489
Compensación
Mr. Saqib Islam, J.D. has been Chief Executive Officer and Director at SpringWorks Therapeutics, Inc. since August 2018. He serves as an Independent Director of Passage Bio, Inc. since March 2019. Mr. Isla...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 6.3yrs | US$18.35m | 0.93% $ 27.1m | |
| Chief Financial Officer | 5.3yrs | US$3.74m | 0.025% $ 729.2k | |
| Chief Operating Officer | 3.8yrs | US$6.64m | 0.21% $ 6.1m | |
| Chief Medical Officer | 3.3yrs | US$4.31m | 0.031% $ 900.4k | |
| Chief Accounting Officer | 4.7yrs | sin datos | 0.0083% $ 240.3k | |
| Chief Scientific Officer | 1.2yrs | sin datos | 0.0075% $ 218.5k | |
| Vice President of Communications & Investor Relations | 6.8yrs | sin datos | sin datos | |
| General Counsel & Secretary | 4.8yrs | US$2.83m | 0.018% $ 531.6k | |
| Chief People Officer | 4.3yrs | US$2.52m | 0.0065% $ 188.6k | |
| Chief Commercial Officer | 3.7yrs | US$4.94m | 0.014% $ 400.4k |
4.5yrs
Permanencia media
56yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de SWTX se considera experimentado (4.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 6.3yrs | US$18.35m | 0.93% $ 27.1m | |
| Independent Director | 5.3yrs | US$520.14k | 0.014% $ 412.6k | |
| Independent Chairman of the Board | 8.8yrs | US$545.14k | 0.41% $ 11.8m | |
| Director | less than a year | sin datos | sin datos | |
| Independent Director | 7.3yrs | US$508.45k | 0.014% $ 412.6k | |
| Independent Director | 2.3yrs | US$507.64k | 0.011% $ 312.2k | |
| Independent Director | 4.5yrs | US$520.14k | sin datos |
5.3yrs
Permanencia media
66yo
Promedio de edad
Junta con experiencia: La junta directiva de SWTX se considera experimentada (5.3 años de antigüedad promedio).